# Systemic Sclerosis Complicated by Rapidly Progressive Osteomyelitis: A Case Report

**Authors:** Angelo Nigro

PMC · DOI: 10.2174/0115733971365099250205151000 · Current Rheumatology Reviews · 2025-02-06

## TL;DR

A patient with systemic sclerosis developed rapidly progressing osteomyelitis, emphasizing the need for early detection and treatment to prevent severe bone damage.

## Contribution

This case report presents a rare and rapidly progressive instance of osteomyelitis in a systemic sclerosis patient.

## Key findings

- Osteomyelitis in systemic sclerosis can progress rapidly despite negative culture results.
- Combination antibiotic therapy led to symptom resolution and partial recovery of affected bone.
- Early radiographic monitoring and intervention are crucial for managing such complications.

## Abstract

Systemic sclerosis (SSc) is an autoimmune disorder characterized by progressive fibrosis and vascular complications. Osteomyelitis is a rare but serious complication in patients with systemic sclerosis, particularly those with advanced vascular compromise. This case is notable for the rapid progression of osteomyelitis and highlights the importance of early intervention and thorough clinical monitoring.

We report the case of a 68-year-old female with SSc (Scl-70 positive), treated with iloprost IV, nifedipine, bosentan, prednisone, and mycophenolate for pulmonary involvement. In January 2024, she developed acrocyanosis and severe pain in the fifth toe of the right foot. A small ulcer formed, and subsequent radiographic evaluation revealed rapid progression of osteolysis. Despite negative culture swabs, an infectious process was suspected, and combination antibiotic therapy was initiated. This treatment led to a gradual resolution of symptoms, with subsequent imaging showing detachment of the fifth toe.

This case highlights the critical need for vigilant radiographic monitoring and timely antibiotic intervention in patients with SSc who develop vascular complications. Early diagnosis and treatment are crucial for optimizing patient outcomes and preventing severe bone damage.

## Linked entities

- **Chemicals:** iloprost (PubChem CID 5311181), nifedipine (PubChem CID 4485), bosentan (PubChem CID 104865), prednisone (PubChem CID 5865), mycophenolate (PubChem CID 6918995)
- **Diseases:** systemic sclerosis (MONDO:0005100), osteomyelitis (MONDO:0005246)

## Full-text entities

- **Diseases:** detachment of the fifth toe (MESH:C565090), bone damage (MESH:D001847), fibrosis (MESH:D005355), osteolysis (MESH:D010014), vascular compromise (MESH:D057772), autoimmune disorder (MESH:D001327), ulcer (MESH:D014456), vascular complications (MESH:D003925), pain (MESH:D010146), infectious (MESH:D003141), Osteomyelitis (MESH:D010019), pulmonary involvement (MESH:C566343), SSc (MESH:D012595)
- **Chemicals:** prednisone (MESH:D011241), iloprost (MESH:D016285), bosentan (MESH:D000077300), nifedipine (MESH:D009543), mycophenolate (MESH:D009173)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12606601/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12606601/full.md

## References

15 references — full list in the complete paper: https://tomesphere.com/paper/PMC12606601/full.md

---
Source: https://tomesphere.com/paper/PMC12606601